Tempus AI is an American health technology company[1] founded in 2015 by Eric Lefkofsky in Chicago, Illinois.[2] It was established by Eric soon after his wife was diagnosed with breast cancer.[3] Tempus uses data and artificial intelligence to create precision medicine solutions, including diagnostics,[4] for oncology, cardiology, and depression. The company went public on June 14, 2024[5][6] under the ticker symbol "TEM."
Business Tempus is headquartered in Chicago, with offices in New York and San Francisco. It has three CAP/CLIA labs in Chicago, Atlanta, and Research Triangle Park.[7] Tempus does next-generation sequencing primarily for cancer patients, and pharmacogenomic testing for patients with depression.
Tempus investors include Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, Revolution LLC, Google LLC, etc.[8]
References
[edit]- ^ "16. Tempus". CNBC. May 25, 2021.
- ^ Rosenbaum, Leah (December 10, 2020). "EXCLUSIVE: Billionaire Eric Lefkofsky's Tempus Raises $200 Million to Bring Personalized Medicine to New Diseases". Forbes.
- ^ Liu, Phoebe. "Billionaire Groupon Founder Eric Lefkofsky's Health Tech Company Goes Public—His Fourth IPO". Forbes. Retrieved June 20, 2024.
- ^ Or, Amy (June 14, 2024). "Medical Data Firm Tempus AI Rises After $410.7 Million IPO". Bloomberg.
- ^ de León, Riley (June 14, 2024). "Google-backed Tempus AI closes first day of trading up 9% in Nasdaq stock market debut". CNBC.
- ^ de León, Riley (June 14, 2024). "Google-backed Tempus AI closes first day of trading up 9% in Nasdaq stock market debut". CNBC.
- ^ https://www.newsobserver.com/news/business/article253261478.html
- ^ "SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO". Reuters. June 5, 2024.